Search clinical trials for: ACC-001 3 μg/ QS-21 50 μg

Total 13 results

Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

Alzheimer's Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Terminated

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old

COVID-19 | SARS-CoV-2

Australia, United States, Philippines
Pfizer
Janssen Alzheimer Immunotherapy (JAI) Research and Development, LLC

Completed

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Spain, France, Germany
Mylan Pharmaceuticals Inc

Completed

A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers

Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Japan
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease

Alzheimer Disease

Japan
AstraZeneca

Completed

Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects

Asthma (Part 1) | COPD (Part 2)

United Kingdom
Karolinska Institutet

Terminated

Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture (GDHT)

Femoral Fracture

Sweden
University of Washington
Genentech, Inc.

Recruiting

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone...

United States
University of Southern California
National Cancer Institute (NCI); Amgen

Terminated

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma | Double Expressor Lymphoma | High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements

United States

Search clinical trials for: ACC-001 3 μg/ QS-21 50 μg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations